protein phosphatase 1 regulatory subunit 12B pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PPP1R12BP2 profile across patient tissues and cancer cell-line models. PPP1R12BP2 expression is associated with patient survival in 3 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PPP1R12BP2 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, PPP1R12BP2 RNA expression shows 493 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, PRAD, and LUAD as cancer lineages where PPP1R12BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R12BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R12BP2 survival associations across molecular data types. PPP1R12BP2 RNA expression shows survival associations in the most cancer types (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R12BP2 RNA expression–survival associations across cancer types. High PPP1R12BP2 expression shows unfavorable associations in SKCM, HNSC and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PPP1R12BP2 RNA expression.
This table summarizes PPP1R12BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPP1R12BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R12BP2 shows higher tumor expression in PRAD. The PRAD box plot shows higher PPP1R12BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .023).
This table shows molecular features associated with PPP1R12BP2 in patient tissues and cancer cell lines. In patient samples, PPP1R12BP2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
